Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
-
Clinical Trial Information
Trial Contact: Parker, Melanie; Armatti, Julie M; Frankos, Marie; Torrescano, Tanner; Jones, Jamie; Singh, Sarah H
Trial Phone: 321-843-1036 ; 321-843-5284 ; 321-842-8738 ; 321-841-8271 ; 3218412008 ; 321.841.7561
-
IRB No: 24.169.11
Protocol Abbrev: BCC022
Principal Investigator: Jaime C Gonzalez, MD
Phase: Drug: Phase II
Age Group: Pediatric
Secondary Protocol No: BCC022
Treatment: Drug: Tipifarnib; Drug: Naxitamab
Therapies Involved: Medication
ClinicalTrials.gov ID: NCT06540963
-
Objective
Test the safety and tolerability of tipifarnib in combination with naxitimab in patients with cancer
To determine the activity of study treatments chosen based on:
How each subject responds to the study treatment
How long a subject lives without their disease returning/progressing -
Key Eligibility
Age:
Subjects must be age ≤ 21 years at initial diagnosis. Subjects must be >12 months of age at enrollment. Safety Run-In (first 6 subjects) must be age 6 years or older.
Pathology: All subjects must have a pathologically confirmed diagnosis of neuroblastoma at any point in their treatment.
